Your Messages Inbox
Your Article Summary
See Latest ArticlesProtocol for a randomized controlled trial on risk adapted damage control orthopedic surgery of femur shaft fractures in multiple trauma patients
Trials, 08/20/09
Rixen D et al. – The Damage Control Study is the first to evaluate the risk adapted damage control orthopedic surgery concept of femur shaft fractures in multiple trauma patients in a randomized controlled design. The trial investigates the differences in clinical outcome of two currently accepted different ways of treating multiple trauma patients with femoral shaft fractures. This study will help to answer the question whether the "early total care" or the damage control" concept is associated with better outcome.
Related Articles
The Prevalence of Perioperative Visual Loss in the United States: A 10-Year Study from 1996 to 2005 of Spinal, Orthopedic, Cardiac, and General Surgery
Anesthesia & Analgesia, 10/23/09
Relevance Score: 66%
Postoperative Urinary Retention
Anesthesiology Clinics, 10/16/09
Relevance Score: 66%
Impact of a comanaged geriatric fracture center on short-term hip fracture outcomes
Archives of Internal Medicine, 10/14/09
Relevance Score: 66%
Motion-preserving Surgery Can Prevent Early Breakdown of Adjacent Segments: Comparison of Posterior Dynamic Stabilization With Spinal Fusion
Journal of Spinal Disorders & Techniques, 10/07/09
Relevance Score: 66%
Continuous Vertical Infraclavicular Brachial Pelxus Block for Post Operative Pain Relief in Orthopaedics Surgery
Journal of Anaesthesiology Clinical Pharmacology, 10/05/09
Relevance Score: 66%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09
Article Search
Sponsor